This trial tests the safety and effectiveness of a new medicine for healthy male volunteers. Results will help predict how the drug works in multiple doses.
5 Primary · 1 Secondary · Reporting Duration: Day 64
3 Treatment Groups
1 of 3
1 of 3
1 of 3
48 Total Participants · 3 Treatment Groups
Primary Treatment: GB-5001 · Has Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Age 18 - 55 · Male Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is it permissible for me to join this clinical investigation?
"Those suffering from Alzheimer's and between the ages of 18 to 55 may be eligible for this trial. We are seeking approximately 48 participants in total." - Anonymous Online Contributor
What is the aggregate of participants signing up for this experiment?
"Correct. According to the clinicaltrials.gov website, this medical trial is currently seeking participants after being first published on August 26th 2022 and updated recently on November 9th 2022. The research requires 48 patients from a single site for successful completion." - Anonymous Online Contributor
Are octogenarians allowed to partake in this research trial?
"This trial only accepts applicants aged between 18 and 55. For younger individuals, there are 23 trials available and for those over 65, 536 opportunities exist." - Anonymous Online Contributor
Is there still an opportunity for individuals to participate in this research?
"According to the clinicaltrials.gov data, this trial is in a state of active recruitment since its initial posting on August 26th 2022 and subsequent update on November 9th 2022." - Anonymous Online Contributor
What potential risks do patients face when administered GB-5001?
"As this is an early stage trial, the safety of GB-5001 was assessed to be a 1 on our rating scale. This grade reflects limited data supporting efficacy and only preliminary evidence indicating its safety." - Anonymous Online Contributor